CCTG

CAPTUR | PM.1

NCT03297606

PM.1

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | A Phase II Basket Trial

Status:

Recruiting

26459-200.png

II

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Targeted therapy based on genetic profiling:

Treatment Arms

o Experimental: Group 1
VEGFR1, VEGFR2, VEGFR3

o Experimental: Group 2
BCR-ABL, SRC

o Experimental: Group 3
ALK, ROS1, MET

o Experimental: Group 4
KIT, PDGFRA, PDGFRB, ABL1

o Experimental: Group 5
EGFR

o Experimental: Group 6
high mutation burden, POLE, POLD1

o Experimental: Group 7
BRCA1, BRCA2, mutations in HRD

o Experimental: Group 8
CDKN2A, CDK4, CCND1, SMARCA4

o Experimental: Group 9
CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL

o Experimental: Group 10
AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2

o Experimental: Group 11
ERBB2

o Experimental: Group 12
BRAFV600

o Experimental: Group 13
PTCH1, SMO